<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/15C24526-2ADD-447A-A6A5-81EB05E6C8C7"><gtr:id>15C24526-2ADD-447A-A6A5-81EB05E6C8C7</gtr:id><gtr:name>Innovate Pharmaceuticals Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1A3C4B4D-A492-43D4-BD25-729BD718D1E9"><gtr:id>1A3C4B4D-A492-43D4-BD25-729BD718D1E9</gtr:id><gtr:name>University of Wolverhampton</gtr:name><gtr:address><gtr:line1>Molineux Street</gtr:line1><gtr:line4>Wolverhampton</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>WV1 1SB</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A7D848E-72A7-46F1-8634-A477FFBA86DD"><gtr:id>5A7D848E-72A7-46F1-8634-A477FFBA86DD</gtr:id><gtr:name>Centre for Genetic Engineering and Biotechnology (CIGB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Royal (Dick) School of Veterinary Scienc</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/15C24526-2ADD-447A-A6A5-81EB05E6C8C7"><gtr:id>15C24526-2ADD-447A-A6A5-81EB05E6C8C7</gtr:id><gtr:name>Innovate Pharmaceuticals Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1A3C4B4D-A492-43D4-BD25-729BD718D1E9"><gtr:id>1A3C4B4D-A492-43D4-BD25-729BD718D1E9</gtr:id><gtr:name>University of Wolverhampton</gtr:name><gtr:address><gtr:line1>Molineux Street</gtr:line1><gtr:line4>Wolverhampton</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>WV1 1SB</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A7D848E-72A7-46F1-8634-A477FFBA86DD"><gtr:id>5A7D848E-72A7-46F1-8634-A477FFBA86DD</gtr:id><gtr:name>Centre for Genetic Engineering and Biotechnology (CIGB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/886C7E0C-3486-4BEB-BA3D-557BD86F01E6"><gtr:id>886C7E0C-3486-4BEB-BA3D-557BD86F01E6</gtr:id><gtr:firstName>Lesley</gtr:firstName><gtr:surname>Stark</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ001481%2F1"><gtr:id>8F4D0632-C015-4964-B4FA-3DF0F3715E38</gtr:id><gtr:title>IDENTIFICATION OF NUCLEAR PATHWAYS THAT ARE CAUSALLY INVOLVED IN NUCLEOLAR TARGETING OF NF-KAPPAB/RELA.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J001481/1</gtr:grantReference><gtr:abstractText>Colorectal cancer is the most common cause of cancer death amongst the non-smoking population in the UK and is a major public health issue for the British population. Unequivocal evidence indicates that aspirin and related agents can prevent colorectal cancer and cause regression of this disease. However, the potential of aspirin-like agents is limited by their toxicity. In this lab, we have been undertaking studies to understand how aspirin-like agents act against colon cancer cells, in order to develop more effective and specific alternatives. We have shown that these agents cause a molecule involved in the regulation of cell growth and death, RelA, to move from the cytoplasmic compartment of the cell to the nucleoplasmic compartment then to a nuclear compartment called the nucleolus. We have also shown that movement of RelA from the nucleoplasm to the nucleolus is important for the ability of aspirin-like agents to kill colon cancer cells. Furthermore, we have demonstrated that artificially localising RelA to the nucleolus mediates the death of this cell type
The overall objective of this study is to understand how aspirin causes RelA to move from the nucleoplasm to the nucleolus. Identifying the cellular pathways involved will allow the design of preventative/therapeutic agents that force RelA into the nucleolar compartment to kill colon cancer cells. We have already shown that a molecule called COMMD1 is important in causing RelA to go to the nucleolus in response to aspirin and that COMMD1 acts by linking a regulatory molecule called ubiquitin, to RelA.

The specific objectives of this proposal are:

1. To identify molecules that, alongside COMMD1, are important for linking ubiquitin to RelA after aspirin treatment. We will examine the role of candidate molecules that have previously been identified as playing a role in linking ubiquitin to RelA. We will also isolate COMMD1 from aspirin treated cells and use a technique called mass spectrometry to identify molecules that bind to COMMD1 in response to the agent. We will examine how aspirin effects these molecules and how aspirin upregulates COMMD1.
2. Identification of the specific parts of RelA that are linked to ubiquitin in response to aspirin and the nature of this linkage. Ubiquitin is generally linked onto proteins at specific sites called lysines. We will identify the lysines of RelA that ubiquitin is linked to in response to aspirin. Ubiquitin also links to itself on lysine molecules to form chains. We will determine which lysine on ubiquitin is critical for nucleolar translocation of RelA using, amongst other approaches, a single cell assay where ubiquitination can be visualised.
3. Identification of proteins that transport ubiquitin-linked RelA to the nucleolus. When ubiquitin is linked to a molecule, specific proteins bind to that molecule. Therefore, we suggest that when ubiquitin is linked to RelA, specific molecules bind RelA and transport the protein to the nucleolus. We will use a labelling approach and mass spectrometry to identify proteins that bind specifically to aspirin-induced, ubiquitin-linked RelA. 
 
These complementary approaches will allow us to understand the basic science of how RelA is regulated in the nucleoplasm, how linking ubiquitin to RelA causes it to go to the nucleolus and how proteins similar to RelA locate to different compartments in the cell. More importantly, these studies may reveal a way to chemically manipulate these pathways to mimic effects of aspirin on colon cancer cells.</gtr:abstractText><gtr:technicalSummary>Objective 1. Identification of the COMMD1 complex that ubiquitinates RelA in response to aspirin. Approaches that will be used to complete this objective include depletion of candidate proteins using siRNA followed by immunocytochemistry to detect nucleolar translocation of RelA and Ni-agarose precipitation of 6HisUb followed by anti-RelA western blot analysis to detect ubiquitination of the protein. We will also use a proteomics approach to identify novel, aspirin-induced, COMMD1 binding proteins. GST-COMMD1 will be isolated from cells +/- aspirin. COMMD1 binding proteins will be identified by SDS PAGE and mass spectrometry of excised bands. Immunocytochemistry, western blot analysis and qRTPCR will be used to analyse the effects of aspirin on components of the complex and the mechanisms by which aspirin causes increased cellular levels of COMMD1.
Objective 2. Identification of the lysine residues of RelA that are ubiquitinated in response to aspirin and the nature of this ubiquitination. Deletion and site directed mutagenesis will be used to identify domains and lysine residues of RelA important for ubiquitination. We will use ubiquitin-mediated fluorescence complementation (UbFC) assays, expression of mutated ubiquitin and linkage specific antibodies, to identify the ubiquitin linkages important for nucleolar translocation of RelA. 
Objective 3. Identification of proteins that transport ubiquitinated RelA to the nucleolus. We propose a novel proteomic approach to identify proteins that specifically bind to aspirin-induced, ubiquitinated RelA which involves a combination of isolation of ubiquitinated RelA and stable isotope labelling of amino acids in culture (SILAC). Once binding proteins are identified, techniques outlined in objective 1 will be used to determine their role in aspirin-mediated nucleolar translocation of RelA.</gtr:technicalSummary><gtr:potentialImpactText>The beneficiaries of this research will be:
1. Academia: As outlined in the academic beneficiaries section, this research will be of considerable and immediate interest to national and international researchers in a number of academic fields including colon cancer prevention nucleolar transport pathways, regulation of cell growth and death by NF-kB and nuclear regulation of RelA. These scientists will benefit from theoretical advancements in the fields, as well as gaining access to the biological tools that will be generated as part of the research and any methodologies developed.
2. Pharmaceutical companies: Uncontrolled NF-kB activity is a contributory factor in a number of common diseases. Therefore, pharmaceutical companies are extremely interested in developments that may lead to novel methods to inhibit this activity. Identification of pathways that cause RelA to translocate to the nucleolus has the very real potential of revealing targets for drugs that manipulate these pathways to switch off NF-kB. As the nucleolar presence of RelA causes apoptosis, the research will also be of interest to companies interested in developing novel anti-cancer agents.
3. Patients and health professionals: Identifying the mechanisms by which aspirin upregulates COMMD1 may have an immediate impact on colorectal cancer patients as it may reveal biomarkers of response in clinical trials of chemopreventative agents. In the long term, understanding the mechanisms by which NSAIDs prevent colorectal cancer may lead to the development of novel agents that could be used to prevent this disease in high risk patients. 
4. General public: Media publicity of grant awards and published work will raise awareness of this preventable disease and may prompt the general public to question their risk.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-09-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-09-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>334194</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Innovate Pharmaceuticals Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Innovate Pharmaceuticals</gtr:description><gtr:id>CF85CF1B-3664-4CEF-9B5A-14A5A22FB9F7</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>58be934f8af403.42618913-1</gtr:outcomeId><gtr:partnerContribution>Innovate pharmaceutical have provided liquid aspirin. They have also provided funding for the project</gtr:partnerContribution><gtr:piContribution>Innovate have provided us with a new form of liquid aspirin. We are testing this to determine efficacy against colorectal cancer and mechanism of action</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Genetic Engineering and Biotechnology (CIGB)</gtr:collaboratingOrganisation><gtr:country>Cuba, Republic of</gtr:country><gtr:description>CIGB collaboration</gtr:description><gtr:id>2E4CF1B8-FDE0-4E1F-8FA3-C40B466A148A</gtr:id><gtr:impact>On the basis of the collaboration, a PhD student from CIGB obtained a travel fellowship from the Journal of Cell Science (2013) and EMBO (2015) to undertake work in my lab. A manuscript &amp;quot;A novel, COMMD1 targeting peptide, CIGB-552, acts synergistically with aspirin on NF-kappaB signalling and apoptosis&amp;quot; has been submitted to Scientific reports.
As a result of the collaboration, myself and the lab at CIGB are jointly organisng the 1st Cuban NF-kappaB symposia, to be held at the second international convention Immunopharamacology, Varadero, 2017. This will bring european scientists to Cuba which will help form new collaborations.</gtr:impact><gtr:outcomeId>542d4982092d99.01607365-1</gtr:outcomeId><gtr:partnerContribution>The partners have provided a PhD student to work on the joint project. They have also provided my lab with the peptide that they are developing that targets COMMD1 to use in our studies.</gtr:partnerContribution><gtr:piContribution>i contributed significantly in the preparation of a travel fellowship to allow a PhD student from this department to work in my lab . I am now the phd students second supervisor and have input into the direction of the project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heriot-Watt University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Biological Chemistry, Biophysics and Bioengineering (IB3)</gtr:department><gtr:description>Herriot Watt</gtr:description><gtr:id>0507D5AB-2D42-4658-A9C0-34EB81FE1B19</gtr:id><gtr:impact>Submitted joint BBSRC grant</gtr:impact><gtr:outcomeId>e4E5ngnhBtV-1</gtr:outcomeId><gtr:partnerContribution>Provided facilities and experience in high resolution microscopy.</gtr:partnerContribution><gtr:piContribution>Provided biological question and undertook basic molecular biology and prepared grant application</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Wolverhampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of wolverhampton</gtr:description><gtr:id>98859AA1-8B8A-4CB8-9D59-127A746961E7</gtr:id><gtr:impact>Publication- Identification of aspirin analogues that repress NF-?B signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo. Projects involved chemists and molecular biologists. Based on this publication a new collaboration was initiated with Innovate Pharmaceuticals to test a new liquid form of aspirin in my lab.</gtr:impact><gtr:outcomeId>54494a6600eb05.42513640-1</gtr:outcomeId><gtr:partnerContribution>My partners generated and refined aspirin analogues.</gtr:partnerContribution><gtr:piContribution>Our collaborators generated aspirin analogues and we tested the anti-tumour properties and mechanisms of action of the analogues in my lab.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Genetic Medicine</gtr:department><gtr:description>COMMD1 Lynch syndrome patients</gtr:description><gtr:id>031E79C0-9C09-4704-BCD2-147C6106BA77</gtr:id><gtr:impact>Collaboration just started</gtr:impact><gtr:outcomeId>58be960fb55f51.44312124-1</gtr:outcomeId><gtr:partnerContribution>The CAPP2 project was run by our partners - randomised trial to determine whether aspirin prevents colon tumourigenesis in Lynch syndrome patients. Partners collected and processed biopsies. They have provided sections of these biopsies for us to analyse the association between COMMD1 and aspirin response.</gtr:partnerContribution><gtr:piContribution>Analysing CAPP2 patient biopsies for COMMD1 levels using immunohistochemistry</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B8B3E27B-229D-4CD2-98C5-9F7715D28CAB</gtr:id><gtr:impact>Public talk at Edinburgh International Science Festival. As a result.

Research reported in many national papers. Awareness raised regarding Bowel cancer</gtr:impact><gtr:outcomeId>G3W1cPJGRDm</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencefestival.co.uk/whats-on/categories/talk/healthy-lunches-aspirin-a-day</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International chair - 1st cuban NF-kappaB symposia</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E8A1F2E1-188C-4E01-9BF4-988CE7A9813A</gtr:id><gtr:impact>organisation of 1st Cuban NF-kappaB symposia-purpose to bring to gether NF-kB community with medicinal chemists. this allows scientists to visit cuba and interact with Cuban scientists.</gtr:impact><gtr:outcomeId>58be9b3ae3fde0.14442142</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Third sector organisations</gtr:primaryAudience><gtr:url>http://www.immunovaccipharmacuba.com/index.php?module=general10</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Edinburgh)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4E8071E4-8FB6-4999-88EB-2D5F5685A29D</gtr:id><gtr:impact>30 pupils engaged in a workshop. This sparked a lot of interest/questions and interest in science as a career.

School increased engagement with scientists</gtr:impact><gtr:outcomeId>PWWUwKkTmCY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Company of Biologists small meeting grant</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Company of Biologists</gtr:fundingOrg><gtr:id>FDA4F56C-216E-4292-A897-D08AC87A2F30</gtr:id><gtr:outcomeId>58be99bded6f18.61525110</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>6C73D7FA-E285-411C-894C-FA2045AB22CC</gtr:id><gtr:outcomeId>54494d631b4912.28544313</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B117781F-70C7-43FE-955A-2F53977971DF</gtr:id><gtr:title>Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f3ab551fcd464f059cbc88848d9d463"><gtr:id>3f3ab551fcd464f059cbc88848d9d463</gtr:id><gtr:otherNames>Novo SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a34f5d1072040.88090929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4361E21D-7C16-434C-8B13-AF92A5D52033</gtr:id><gtr:title>Identification of a novel, NF-?B nucleolar stress response pathway</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/153374a71b6b5db7df216b1c08d64f74"><gtr:id>153374a71b6b5db7df216b1c08d64f74</gtr:id><gtr:otherNames>Chen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>56d813328fab57.78375455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AD6871E-09AF-44AC-AB4B-86A11B85F8DC</gtr:id><gtr:title>A Proteomic Approach to Analyze the Aspirin-mediated Lysine Acetylome.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/344b6e5aab54f1ccb588754097718a4a"><gtr:id>344b6e5aab54f1ccb588754097718a4a</gtr:id><gtr:otherNames>Tatham MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>58bc87d8f06190.77948136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D87DAF6-D69F-48EF-BDEA-3E3681077D47</gtr:id><gtr:title>Identification of aspirin analogues that repress NF-?B signalling and demonstrate anti-proliferative activity towards colorectal cancer in&amp;nbsp;vitro and in&amp;nbsp;vivo.</gtr:title><gtr:parentPublicationTitle>Oncology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f14307245892bbb3c282fbfd26c24b76"><gtr:id>f14307245892bbb3c282fbfd26c24b76</gtr:id><gtr:otherNames>Claudius AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1021-335X</gtr:issn><gtr:outcomeId>542d4d9fcf7e61.89362861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88C0A51A-61C3-4213-8477-389091D1147C</gtr:id><gtr:title>Aspirin Prevention of Colorectal Cancer: Focus on NF-?B Signalling and the Nucleolus.</gtr:title><gtr:parentPublicationTitle>Biomedicines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/153374a71b6b5db7df216b1c08d64f74"><gtr:id>153374a71b6b5db7df216b1c08d64f74</gtr:id><gtr:otherNames>Chen J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2227-9059</gtr:issn><gtr:outcomeId>5a34f597d35d10.47840610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D99AE18B-B374-4FBE-A273-7D4089803715</gtr:id><gtr:title>Identification of P62(SQSTM1) as a nucleolar transporter for NF-KappaB/RelA and other ubiquitinated proteins</gtr:title><gtr:parentPublicationTitle>Submitted Mol Cell Biol</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0736838580443c6f838334867105ee12"><gtr:id>0736838580443c6f838334867105ee12</gtr:id><gtr:otherNames>Morin P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:outcomeId>56d82924365f16.54091906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6A3EA7C-1A76-414A-AA20-7039AB791F5F</gtr:id><gtr:title>p300-mediated acetylation of COMMD1 regulates its stability, and the ubiquitylation and nucleolar translocation of the RelA NF-?B subunit.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/288c9fbb84fbcddf4cf1bcf56396abe9"><gtr:id>288c9fbb84fbcddf4cf1bcf56396abe9</gtr:id><gtr:otherNames>O'Hara A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>542d4da01ab1f1.96390253</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J001481/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>